ALPINE IMMUNE SCIENCES, INC. |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 65 USD | +0.05% |
|
+0.08% | +240.98% |
| May. 10 | Alpine Immune Sciences, Vertex Pharmaceuticals Deal Crosses Another Milestone | MT |
| May. 09 | Alpine Immune Sciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Presenter SpeechMichael Ulz (Analysts)All right. Let's get started, everyone. Thanks for joini...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Alpine Immune Sciences, Inc. is a clinical-stage biopharmaceutical company, which is engaged in discovering and developing protein-based immunotherapies to treat autoimmune and inflammatory diseases. The Companyâs approach includes a proprietary scientific platform that converts native immune system proteins into differentiated, multi-targeted therapeutics. Its ALPN-303 (povetacicept) is a dual antagonist of the B cell activating factor (BAFF) and a proliferation, inducing ligand (APRIL), cytokines, which play key roles in the pathogenesis of multiple autoimmune diseases via their contribution to the activation, differentiation and/or survival of B cells, particularly antibody-secreting cells, as well as T cells and innate immune cells. Its ALPN-101 (acazicolcept) is a dual Inducible T cell Costimulator (ICOS), and CD28 antagonist intended for the treatment of autoimmune and inflammatory diseases.
Calendar
2024-08-12
- Q2 2024 Earnings Release (Projected)
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
C-
Sell
Buy
Mean consensus
HOLD
Number of Analysts
8
Last Close Price
64.96
USD
Average target price
62
USD
Spread / Average Target
-4.56%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +240.98% | 4.46B | |
| +9.47% | 114B | |
| +11.57% | 104B | |
| -13.79% | 22.41B | |
| -1.05% | 22.28B | |
| -5.29% | 19.07B | |
| -38.29% | 18B | |
| -4.61% | 17.89B | |
| +7.48% | 14.28B | |
| +35.98% | 12.55B |
- Stock Market
- Equities
- ALPN Stock
- News Alpine Immune Sciences, Inc.
- Transcript : Alpine Immune Sciences, Inc. Presents at Morgan Stanley 21st Annual Global Healthcare Conference 2023, Sep-13-2023 10